



Adam Telner MD, FRCPC, FACP

* Adam Telner provides medical services through Dr. Adam Telner Medicine Professional Corporation

Bayview 1929 Bayview Avenue, Suite 107, 125, Toronto, Ontario, M4G 3E8, Canada Tel (416) 645-2929

CURRICULUM VITAE

Education, Certification & Licenses

| | | |
|-----------|---|--|
| 2020-2022 | ICH-GCP Certification | Syneos Health |
| Jan 2015 | Advanced Cardiac Life Support (ACLS) | ACLS Certification Institute |
| 1985 | F.A.C.P | American College of Physicians, USA |
| 1985 | Certification, Endocrinology & Metabolism | Royal College of Physicians & Surgeons of Canada, Toronto ON |
| 1983 | Certification, Endocrinology & Metabolism | American Board of Internal Medicine, USA |
| 1978 | Certification, Internal Medicine | American Board of Internal Medicine, USA |
| 1978 | Certificate (FRCPC), Internal Medicine | Royal College of Physicians & Surgeons of Canada, Toronto ON |
| 1973 | Masters of Science, Experimental Medicine | McGill University, Montreal QC |
| 1972 | Medical Doctorate | McGill University, Montreal QC |
| 1968 | Honours Bachelor of Science, Genetics | McGill University, Montreal QC |

Professional Activities

| | | |
|-------------------|--------------------------------|--|
| 2010-Present | Sub-Investigator | LMC Clinical Research Inc. |
| 2010-Present | Associate, Endocrinologist | LMC Diabetes & Endocrinology |
| 1979-2010 | Department of Medical Staff | Queensway Carleton Hospital, Ottawa ON |
| 2004-10 | Consulting Staff | Division of Endocrinology and Metabolism, Ottawa Hospital, Ottawa ON |
| Apr 2002-Apr 2003 | Acting Chief | Department of Geriatrics, Queensway Carleton Hospital, Ottawa ON |
| 1993-1997 | Clinical Tutor Endocrine Block | University of Ottawa, Ottawa ON |
| 1993-2000 | Consulting Staff | Division of Endocrinology and Metabolism, Ottawa Hospital, Ottawa ON |
| 1993-1999 | Chief, Department of Medicine | Queensway Carleton Hospital, Ottawa ON |
| July-Dec 2000 | Endocrinology Consultant | Department of Medicine, Trillium Hospital, Mississauga ON |

Postgraduate Education

| | | |
|-----------|--------------------------------------|---|
| 1972-1973 | Straight Internship in Medicine | Jewish General Hospital, Montreal QC |
| 1973-1974 | Assistant Resident in Medicine | Jewish General Hospital, Montreal QC |
| 1974-1976 | Fellow in Endocrinology & Metabolism | University of Michigan, USAI (Supervisor: Dr. S. Fajans) |
| 1976-1977 | Resident in Endocrinology | Sunnybrook Medical Center, Toronto ON (Supervisor: Dr. R. Sheppard) |
| 1978-1979 | Resident in Medicine | Sunnybrook Medical Center, Toronto ON |

Publications*

- "Prevalence of Obstructive Sleep Apnea in Patients with Metabolic Syndrome", by **A Telner**, A Gervais International Diabetes Federation conference (for Oct 2009)
- "Outcomes of a Multidisciplinary Approach to the Management of the Metabolic Syndrome", by **A Telner**, A Gervais, S Amos; Can Pharm J Jan 2008

Achievements, Associations & Specialties

| | |
|--------------|---|
| Associations | Member, Ontario Medical Association Member, Canadian Society of Endocrinology and Metabolism Member, Canadian Diabetes Association, Clinical and Scientific Section |
| Awards | Commitment to Care & Service Award 2007 Physician & Pharmacist Team (Adam Telner & Alan Gervais) |

Clinical Trials & Research Activities

| | |
|-----------|---|
| 2011-2020 | 1245.20 (BI), TAK-875_304 (Takeda), TAK-875_306 (Takeda), H9X-MC-GBDJ (Eli Lilly), EFC11628 (Sanofi-aventis), EFC12261 (Sanofi-aventis), I5S-MC-EFJE (Eli Lilly), M11-352 (AbbVie), 1245.48 (BI), EFC12347 (Sanofi-aventis), EFC12456 (Sanofi-aventis), CV201-008 (BMS), D1693C00001 (AstraZeneca), RGN11110 (Regeneron), RGN1118 (Regeneron), GSN000200 (Genkyotex), APD356-G000-401 (Eisai), B1481022 (Pfizer), B1481038 (Pfizer), NN9211-3919 (Novo Nordisk), MK8835-002 (Merck), 034HVOL14005 (Retrophin), EFC12404/405 (Sanofi-aventis), 28431754DNE3001 (Janssen), B1481045 (Pfizer), 28431754DIA2004 (Janssen), EFC13799 (Sanofi-aventis), D5881C00004 (AstraZeneca), 200977 (GSK), LX4211.309 (Lexicon), PERL (Joslin Diabetes), LX4211.312 (Lexicon), D1690C00024 (AstraZeneca), NN9828-4150 (Novo Nordisk), PTL901148 (Dexcom), B4801010 (Pfizer), ESR-14-10353 (PHRI), M11-352 (AbbVie), NN1218-3854 (Novo Nordisk), LPS14347 (Sanofi), EFC14834 (Sanofi), CTP-0024 (Senseonics), DRI13940 (Sanofi), 2 (FNIH), K-877-302 (KOWA), CLIK066B2201 (Novartis), GS-US-402-1852 (Gilead), C1171002 (Pfizer), ZP4207-16136 (Zealand), I8H-MC-BDCB (Eli Lilly), BD-SWATCH-015 (BD), BRB-018-001 (BirdRockBio), DRI13940 (Sanofi), FIT (LMC Diabetes & Endocrinology), ZP4207-16137 (Zealand), NN9828-4150 (Novo Nordisk), NN1250-4252 (Novo Nordisk), NN1218-4113 (Novo Nordisk), D5670C00004 (AstraZeneca), EFC14837 (Sanofi), Sci-B-Vac-002 (VBI), CEMA401A2202 (Novartis), EFC14868 (Sanofi), XSGP-303 (Xeris), XSGP-304 (Xeris), NN1250-4419 (Novo Nordisk), T1Dexi (JAEB), FIT Untethered (LMC Clinical Research Inc.), NN9536-4374 (Novo Nordisk), NN9536-4378 (Novo Nordisk), I8B-MC-ITSA (Eli Lilly), EFC14828 (Sanofi), XSMP-204 (Xeris), LPS15544 (Sanofi), I8F-MC-GPGM (Eli Lilly), NN9535-4321 (Novo Nordisk), NN9535-4506 (Novo Nordisk), NN9535-4352 (Novo Nordisk), 1245-0137 (UBC), I8B-MC-ITRO (Eli Lilly), GS-US-223-1017 (Gilead), PTL-903076 (Dexcom), AT-001-2001 (Applied Therapeutics), etc. |
| 2010 | 28431754DIA3015 (J&J), TRX4_DM_013_CAN_09 (Tolerx), TRX4_DM_017_CAN_10 (Tolerx), Stability (GSK), EFC10781 (Sanofi-aventis), EFC6014 (Sanofi-aventis), EFC6016 (Sanofi-aventis), AVD111960 (GSK), 1245.20 (BI), NN1250-3643 (Novo Nordisk), MB102-029 (BMS), H9X-MC-GBDN (Eli Lilly) |

>20 years of research experience, 10 clinical trials

* 16 publication in total. Detailed list available upon request.